Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value d

Bank of America Corp DE lifted its stake in Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 49.2% in t

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial,

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial,

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with

Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd., and Cullinan Therapeutics Inc. (NASDAQ:CGEM) on

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating a

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interi

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the an

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion st

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises

Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a clinical-stage biopharmaceutical

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGF

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato

New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating p

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to ad

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating p

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a cl

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.75) per share which beat the an

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a

https://www.sec.gov/Archives/edgar/data/1789972/000119312526183596/d587157ds3asr.htm

NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meanin

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceuti

Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)

Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Lee

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the an

Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) wit

Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a B

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a